Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹1,09,334 Cr
Revenue (TTM)
₹32,644 Cr
Net Profit (TTM)
₹5,725 Cr
ROE
18.6 %
ROCE
23.3 %
P/E Ratio
19.3
P/B Ratio
3.3
Industry P/E
37.52
EV/EBITDA
11.6
Div. Yield
0.6 %
Debt to Equity
0.1
Book Value
₹400.5
EPS
₹67.8
Face value
1
Shares outstanding
834,581,775
CFO
₹34,519.20 Cr
EBITDA
₹44,523.80 Cr
Net Profit
₹28,197.80 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Dr. Reddy'S Labs
| -5.6 | -0.8 | 18.1 | 0.5 | 14.3 | 11.0 | 5.8 |
|
BSE Sensex
| 6.6 | 1.5 | 10.7 | 4.3 | 15.8 | 18.0 | 11.5 |
|
BSE Healthcare
| -0.6 | 3.8 | 10.7 | 17.3 | 26.9 | 22.4 | 10.2 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Dr. Reddy'S Labs
| 19.3 | 36.8 | -13.6 | -6.4 | 80.8 | 10.3 | 8.8 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
|
BSE Healthcare
| 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 | -5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Dr. Reddy'S Labs
|
1,310.5 | 1,09,334.4 | 32,643.9 | 5,725.2 | 20.7 | 18.6 | 19.3 | 3.3 |
| 34,485.0 | 73,224.0 | 6,409.2 | 1,414.4 | 25.3 | 36.5 | 51.8 | 17.3 | |
| 4,877.3 | 58,259.2 | 12,964.5 | 2,216.0 | 16.6 | 18.4 | 26.9 | 4.9 | |
| 1,185.1 | 68,796.0 | 31,723.7 | 3,515.3 | 15.5 | 11 | 19.7 | 2.1 | |
| 1,510.5 | 1,22,039.1 | 27,547.6 | 5,291.1 | 21.9 | 18.3 | 23.1 | 3.9 | |
| 1,978.6 | 90,311.1 | 22,707.9 | 3,306.3 | 18.0 | 20 | 27.5 | 5.2 | |
| 2,410.4 | 99,610.0 | 12,279.3 | 1,998.9 | 19.6 | 16 | 50 | 7.0 | |
| 1,679.9 | 4,03,040.3 | 52,578.4 | 10,980.1 | 23.3 | 16.2 | 36.9 | 5.6 | |
| 3,352.3 | 1,13,399.5 | 11,516.1 | 1,911.3 | 25.4 | 26.5 | 59.3 | 14.9 | |
| 998.8 | 1,00,512.7 | 23,241.5 | 4,614.8 | 26.2 | 20.4 | 22.2 | 4.2 |
A hunt for quality large caps available cheap
3 min read•By Jugal Harpalani
2 min read•By Mohammed Ekramul Haque
3 min read•By Research Desk
Who wins in India: Value or Growth?
3 min read•By Kumar Shankar Roy
FIIs Vs DIIs: Different strokes
3 min read•By Kumar Shankar Roy
Grab top stocks quoting at a discount
2 min read•By Mohammed Ekramul Haque
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The... company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. Read more
Incorporated
1984
Chairman
K Satish Reddy
Managing Director
GV Prasad
Group
Dr. Reddy's
Headquarters
Hyderabad, Telangana
Website
Looking for more details about Dr. Reddy's Laboratories Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View Announcements
The total asset value of Dr Reddy's Laboratories Ltd stood at ₹ 48,023 Cr as on 31-Mar-25
The share price of Dr Reddy's Laboratories Ltd is ₹1,310.50 (NSE) and ₹1,310.05 (BSE) as of 07-Jul-2025 IST. Dr Reddy's Laboratories Ltd has given a return of 14.28% in the last 3 years.
Dr Reddy's Laboratories Ltd has a market capitalisation of ₹ 1,09,334 Cr as on 07-Jul-2025. As per Value Research classification, it is a Large Cap company.
The P/B ratio of Dr Reddy's Laboratories Ltd is 3.27 times as on 07-Jul-2025, a 41% discount to its peers’ median range of 5.53 times.
The P/E ratio of Dr Reddy's Laboratories Ltd is 19.33 times as on 07-Jul-2025, a 48% discount to its peers’ median range of 37.52 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Dr Reddy's Laboratories Ltd and enter the required number of quantities and click on buy to purchase the shares of Dr Reddy's Laboratories Ltd.
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
The promoters of Dr Reddy's Laboratories Ltd are G V PRASAD and SATISH REDDY KALLAM. They collectively own 21.79 per cent of the total equity. The chairman of the company is K Satish Reddy
There is no promoter pledging in Dr Reddy's Laboratories Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
4,02,284
|
|
|
1,22,253
|
|
|
1,13,988
|
|
|
1,00,724
|
|
|
1,00,677
|
|
|
90,286
|
|
|
73,834
|
|
|
69,150
|
|
|
58,405
|
| Dr. Reddy's Laboratories Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
18.61
|
|
Operating margin(%)
|
20.96
|
|
Net Margin(%)
|
16.97
|
|
Dividend yield(%)
|
0.7
|
Yes, TTM profit after tax of Dr Reddy's Laboratories Ltd was ₹5,725 Cr.
₹3.10
(
